01Inhibrx Biosciences reported Q2 2026 earnings per share of -$2.34, missing the consensus estimate of -$2.32 by $0.02 per share on August 13, 2026.
02The company's stock trades at $87.93 with a market capitalization of $1.2 billion.
03Recent earnings history shows a pattern of significant misses, including a -50.3% surprise in Q1 2026 and a -30.1% surprise in Q3 2025, though Q4 2025 beat estimates by 13.9%.
04The company is unprofitable, with negative earnings per share across all reported quarters, indicating it has not yet achieved profitability.
Earnings Results
Inhibrx Biosciences (NASDAQ:INBX) reported quarterly earnings results on August 13, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-2.34, missing the consensus estimate of $-2.32 by $0.02 per share. Revenue came in at , meeting the estimate of .
Company Overview
Inhibrx Biosciences's stock moved following the earnings release. The stock currently trades at $87.93 with a market capitalization of $1.2B.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Inhibrx Biosciences should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.